Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00160557 | Cervix | CC | Wnt signaling pathway | 98/2311 | 444/18723 | 4.82e-09 | 4.65e-07 | 98 |
GO:00512359 | Cervix | CC | maintenance of location | 78/2311 | 327/18723 | 5.18e-09 | 4.92e-07 | 78 |
GO:01987387 | Cervix | CC | cell-cell signaling by wnt | 98/2311 | 446/18723 | 6.16e-09 | 5.58e-07 | 98 |
GO:00301117 | Cervix | CC | regulation of Wnt signaling pathway | 76/2311 | 328/18723 | 3.05e-08 | 2.08e-06 | 76 |
GO:005165110 | Cervix | CC | maintenance of location in cell | 55/2311 | 214/18723 | 6.63e-08 | 3.85e-06 | 55 |
GO:00614588 | Cervix | CC | reproductive system development | 87/2311 | 427/18723 | 1.37e-06 | 4.55e-05 | 87 |
GO:00608287 | Cervix | CC | regulation of canonical Wnt signaling pathway | 58/2311 | 253/18723 | 1.83e-06 | 5.89e-05 | 58 |
GO:00486088 | Cervix | CC | reproductive structure development | 86/2311 | 424/18723 | 1.90e-06 | 5.97e-05 | 86 |
GO:00600707 | Cervix | CC | canonical Wnt signaling pathway | 66/2311 | 303/18723 | 2.47e-06 | 7.35e-05 | 66 |
GO:00107206 | Cervix | CC | positive regulation of cell development | 64/2311 | 298/18723 | 5.69e-06 | 1.41e-04 | 64 |
GO:00513021 | Cervix | CC | regulation of cell division | 39/2311 | 177/18723 | 2.05e-04 | 2.33e-03 | 39 |
GO:00987275 | Cervix | CC | maintenance of cell number | 30/2311 | 134/18723 | 7.98e-04 | 7.00e-03 | 30 |
GO:00301776 | Cervix | CC | positive regulation of Wnt signaling pathway | 31/2311 | 140/18723 | 8.01e-04 | 7.02e-03 | 31 |
GO:00519603 | Cervix | CC | regulation of nervous system development | 77/2311 | 443/18723 | 1.13e-03 | 9.30e-03 | 77 |
GO:00198274 | Cervix | CC | stem cell population maintenance | 29/2311 | 131/18723 | 1.17e-03 | 9.47e-03 | 29 |
GO:00507676 | Cervix | CC | regulation of neurogenesis | 65/2311 | 364/18723 | 1.33e-03 | 1.05e-02 | 65 |
GO:00618425 | Cervix | CC | microtubule organizing center localization | 11/2311 | 33/18723 | 1.42e-03 | 1.11e-02 | 11 |
GO:00507694 | Cervix | CC | positive regulation of neurogenesis | 43/2311 | 225/18723 | 2.25e-03 | 1.61e-02 | 43 |
GO:00219873 | Cervix | CC | cerebral cortex development | 25/2311 | 114/18723 | 2.81e-03 | 1.88e-02 | 25 |
GO:00516425 | Cervix | CC | centrosome localization | 10/2311 | 32/18723 | 3.96e-03 | 2.48e-02 | 10 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ASPM | SNV | Missense_Mutation | | c.6376A>T | p.Met2126Leu | p.M2126L | Q8IZT6 | protein_coding | tolerated(0.22) | benign(0.028) | TCGA-33-4583-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ASPM | SNV | Missense_Mutation | novel | c.1880G>C | p.Arg627Pro | p.R627P | Q8IZT6 | protein_coding | tolerated(0.17) | benign(0) | TCGA-33-AASD-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
ASPM | SNV | Missense_Mutation | | c.6102G>T | p.Met2034Ile | p.M2034I | Q8IZT6 | protein_coding | deleterious(0.03) | possibly_damaging(0.826) | TCGA-34-2600-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ASPM | SNV | Missense_Mutation | novel | c.5687N>A | p.Arg1896Lys | p.R1896K | Q8IZT6 | protein_coding | tolerated(0.19) | benign(0.262) | TCGA-34-2609-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | gemcitabine | PD |
ASPM | SNV | Missense_Mutation | rs143092798 | c.4214G>T | p.Arg1405Leu | p.R1405L | Q8IZT6 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-34-5236-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
ASPM | SNV | Missense_Mutation | | c.3612N>T | p.Glu1204Asp | p.E1204D | Q8IZT6 | protein_coding | tolerated(0.47) | benign(0.028) | TCGA-34-5927-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
ASPM | SNV | Missense_Mutation | novel | c.1261N>G | p.Gln421Glu | p.Q421E | Q8IZT6 | protein_coding | tolerated(0.3) | benign(0) | TCGA-34-8454-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
ASPM | SNV | Missense_Mutation | novel | c.1109N>G | p.Ser370Cys | p.S370C | Q8IZT6 | protein_coding | deleterious(0) | benign(0.339) | TCGA-34-8454-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
ASPM | SNV | Missense_Mutation | novel | c.8601N>T | p.Gln2867His | p.Q2867H | Q8IZT6 | protein_coding | deleterious(0.05) | probably_damaging(0.99) | TCGA-43-3394-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | gemzar | PD |
ASPM | SNV | Missense_Mutation | | c.6015N>T | p.Arg2005Ser | p.R2005S | Q8IZT6 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-46-6026-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | SD |